Oncology News | pharmaphorum

News

Rumour mill says MSD is hunting Harpoon Therapeutics

MSD’s 2023 run of pipeline-building deals looks like it could continue into this year, with reports already emerging that the company is in talks to buy Harpoon Therapeuti

News

AbbVie is big pharma’s first mover in ‘in situ’ cell therapy

AbbVie has signed a wide-ranging collaboration with Umoja Biopharma in the area of ‘in situ’ or in vivo cell therapy, an emerging strategy that does away with the need to

News

Merck bets on Inspirna’s colorectal cancer drug ompenaclid

Germany’s Merck KGaA is paying $45 million upfront for rights to a potentially first-in-class drug for colorectal cancer (CRC) being developed by New York biotech Inspirna

News

Astellas strikes $1.7bn SIRP drug deal with Elpiscience

Astellas has struck a deal with fellow Japanese pharma company Elpiscience to develop up to four cancer immunotherapies that work by revving up the activity of macrophages

News

BMS strikes again, with $4.1bn RayzeBio takeover bid

Bristol-Myers Squibb is having a busy holiday period, signing a $4.1 billion deal to acquire cancer drug developer RayzeBio – its second multibillion-dollar M&A deal i

News

AZ makes another cell therapy play with $1.2bn Gracell buy

AstraZeneca has lined up a $1.2 billion takeover deal for Chinese biotech Gracell Biotechnologies, bolting a series of cell therapies for cancer and autoimmune diseases on

Rumour mill says MSD is hunting Harpoon Therapeutics

AbbVie is big pharma’s first mover in ‘in situ’ cell therapy

Merck bets on Inspirna’s colorectal cancer drug ompenaclid

Astellas strikes $1.7bn SIRP drug deal with Elpiscience

BMS strikes again, with $4.1bn RayzeBio takeover bid

AZ makes another cell therapy play with $1.2bn Gracell buy

CMS aims for broader GLP-1 access via federal programmes

How to meet your physicians where they are online

News

Editor's Picks